PRINCIPLE TRIAL COVID19

 

Clarendon Lodge Medical Practice are involved in a large scale research project exploring potential treatments for COVID19 (coronavirus). It is called the PRINCIPLE TRIAL.

The risk of complications from COVID-19 is generally greater in people aged 50 years and older with underlying health conditions and in those aged 65 years and older. While most infections either do not cause symptoms or are mild, this new viral infection can lead to significant medical problems, hospitalisation, and sometimes death.

Most of the infections are being managed in the community and it is essential that we identify treatments that help to reduce the progression of the disease and therefore the need for hospital admission.

About the trial

As yet, there are currently no known treatments for COVID-19 which have been proven to be effective. Our trial aims to evaluate potential treatments as they are identified. To be able to do this, we aim to test one or more suitable, potential treatments for COVID-19, as soon as they become available.

We want to make treatments that are proven to be effective as widely and as rapidly available as possible. However, we do not want to give people medication that does not work, and that may simply put them at unnecessary risk of side effects.

We will evaluating three treatment options. One is a drug called hydroxychloroquine. This is a drug that is well known and has been used for many years around the world for conditions such as malaria and arthritis, but is not currently used to treat this kind of infection.

The second is a drug called azithromcyin and a well known antibiotic with anti-viral properties. 

The third option is the current usual supportive care.  

Aim of this trial

We aim to find out whether selected treatments given to those at higher risk of becoming more ill when they are infected with COVID-19 can help reduce the need for hospitalisation and the length of stay required, helping people recover quicker and with fewer complications.

All people included in the study will be provided with a test for COVID-19. Some will receive the medication we are testing and some will be allocated to current usual care without the medication we are testing.